Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

Completed · Phase 1

Conditions studied: Bacillus Anthracis (Anthrax) Infection

In brief

The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity.

Key facts

Study ID

NCT01263691

Run by

Emergent BioSolutions

People needed

105

Starts

2010-12-01

Expected to finish

2012-06-01

Last updated by the study team

2024-03-18

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Be between 18 and 50 years of age, inclusive, at the time of enrollment.
• Be in good health as determined by the investigator from medical history and a physical examination.
• If a pre-menopausal female, must be using acceptable methods of birth control.
• Have all hematology and chemistry parameters (measured at Screening) within the laboratory's normal range.
• Have negative values for the following tests at Screening: Hepatitis C antibody, anti-Human Immunodeficiency Virus (Anti-HIV-1/-2/-O), and anti-Hepatitis B Core Antigen (Anti-HBc).
• Be willing and capable of complying with all aspects of the protocol through completion of the required visits.
• Have not donated blood in the preceding 8 weeks and are willing to not donate blood or plasma within 56 days after dosing.
• Have adequate venous access for repeat phlebotomies.
• Have read, understood and signed an informed consent form.

You may not qualify if…

• Key Exclusion Criteria:
• A known anaphylactic response, severe systematic response, or serious hypersensitivity reaction to a prior immunization.
• Prior immunization with anthrax vaccine, recombinant Protective Antigen (rPA) vaccine, or known exposure to anthrax organisms.
• Have previously served in the military or plans to enlist in the military from Screening through Day 84.
• Have participated in anthrax therapeutic or vaccine trials (monoclonal anti-protective antigen (PA) or anthrax immune globulins or anthrax vaccines).
• Participation in any investigational clinical trial within 30 days preceding the Screening visit or planning to participate in a clinical trial requiring dosing through the Day 194 visit.
• A history of drug or alcohol abuse within 12 months prior to Screening, or a positive result on a urine drug screen for amphetamines, barbiturates, benzodiazepines, cocaine, marijuana, methylenedioxymethamphetamine opiates, oxycodone, phencyclidine, propoxyphene, or tricyclic antidepressants.
• Blood pressure greater than 145 millimeters of mercury (mmHg) systolic or 90 mmHg diastolic.
• Past history of significant autoimmune disease such as rheumatoid arthritis, lupus erythematous, psoriasis, glomerulonephritis, or autoimmune thyroiditis.
• A medical condition that, in the opinion of the Principal Investigator (PI), could adversely impact the subject's participation, safety, or conduct of the study.

Where it is running

• Miami Research Associates — Miami, Florida, United States
• North Carolina Clinical Research — Raleigh, North Carolina, United States
• Jean Brown Research — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.